Clinical Trials Directory

Trials / Unknown

UnknownNCT06096493

Prognostic Factors Affecting Recurrence and Disease-Free Survival After Surgical Resection for Cancer Rectum

Predictors of Disease Free Survival After Curative Cancer Rectum Surgery

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
South Valley University · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers

Summary

Tumor recurrence after curative surgical resection for rectal cancer is a serious complication that greatly affects the overall morbidity and the outcome. This study aims to identify the different prognostic factors affecting recurrence and disease-free survival after surgery.

Detailed description

A retrospective analysis of patients operated for cancer rectum with curative intent from. Exclusion criteria will include patients with familial adenomatous polyposis, multiple synchronous or metachronous rectal cancers, and death within 3 months. Incomplete patients' files and patients that lost follow-up will be excluded. Demographic, histopathological, follow up and outcome data will be collected from completed patients' files. Demographics include age, gender, family history, and chief complaint at the presentation. Histopathological data include tumor grade, vascular-perineural invasion, the total number of lymph nodes removed, and positive lymph nodes. Lymph node ratio will be defined as the ratio of positive lymph nodes to the total number of retrieved lymph nodes in a histopathology specimen. Disease-free survival will be calculated for each patient based on the time of surgery to the time of recurrence detection.

Conditions

Interventions

TypeNameDescription
PROCEDUREcurative surgery for cancer rectumCurative surgery for cancer rectum.

Timeline

Start date
2023-05-01
Primary completion
2023-11-01
Completion
2023-12-01
First posted
2023-10-23
Last updated
2023-10-23

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06096493. Inclusion in this directory is not an endorsement.